Pharmacological effects of methylone and MDMA in humans.
3,4-methylenedioxymethamphetamine
3,4-methylenedioxymethcathinone
MDMA
bath salts
methylone
new psychoactive substances
psychostimulants
synthetic cathinones
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
12
2022
accepted:
06
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we aimed to evaluate the acute pharmacological effects of methylone and its abuse potential in humans when compared with that of MDMA following oral administration under controlled conditions. Seventeen participants of both sexes (14 males, 3 females) with a previous history of psychostimulant use completed a randomized, double-blind, placebo-controlled, crossover clinical trial. Participants received a single oral dose of 200 mg of methylone, 100 mg of MDMA, and a placebo. The variables included physiological effects (blood pressure, heart rate, oral temperature, pupil diameter), subjective effects using visual analog scales (VAS), the short form of the Addiction Research Center Inventory (ARCI), the Evaluation of Subjective Effects of Substances with Abuse Potential questionnaire (VESSPA-SSE), and the Sensitivity to Drug Reinforcement Questionnaire (SDRQ), and psychomotor performance (Maddox wing, psychomotor vigilance task). We observed that methylone could significantly increase blood pressure and heart rate and induce pleasurable effects, such as stimulation, euphoria, wellbeing, enhanced empathy, and altered perception. Methylone exhibited an effect profile similar to MDMA, with a faster overall onset and earlier disappearance of subjective effects. These results suggest that abuse potential of methylone is comparable to that of MDMA in humans.
Identifiants
pubmed: 36873994
doi: 10.3389/fphar.2023.1122861
pii: 1122861
pmc: PMC9981643
doi:
Banques de données
ClinicalTrials.gov
['NCT05488171']
Types de publication
Journal Article
Langues
eng
Pagination
1122861Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2023 Poyatos, Pérez-Mañá, Hladun, Núñez-Montero, de la Rosa, Martín, Barriocanal, Carabias, Kelmendi, Taoussi, Busardò, Fonseca, Torrens, Pichini, Farré and Papaseit.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Toxicol (Phila). 2022 Apr;60(4):440-445
pubmed: 34542387
Neuropsychopharmacology. 2012 Apr;37(5):1192-203
pubmed: 22169943
J Med Toxicol. 2012 Mar;8(1):59-61
pubmed: 21755421
Br J Clin Pharmacol. 2000 Feb;49(2):104-9
pubmed: 10671903
Front Psychiatry. 2023 Jan 10;13:1041277
pubmed: 36704743
Biology (Basel). 2021 Aug 17;10(8):
pubmed: 34440023
Addict Biol. 2005 Dec;10(4):321-3
pubmed: 16318952
J Anal Toxicol. 2020 Jan 7;44(1):69-74
pubmed: 30855673
Int J Drug Policy. 2017 Oct;48:91-98
pubmed: 28810159
Int J Mol Sci. 2022 Nov 23;23(23):
pubmed: 36498963
Curr Neuropharmacol. 2011 Mar;9(1):58-62
pubmed: 21886563
Front Psychiatry. 2017 Nov 17;8:232
pubmed: 29204126
Anal Bioanal Chem. 2013 May;405(12):4067-76
pubmed: 23471370
Am J Forensic Med Pathol. 2013 Mar;34(1):26-8
pubmed: 23403480
Scand J Trauma Resusc Emerg Med. 2017 Mar 7;25(1):26
pubmed: 28264690
J Anal Toxicol. 2017 Jun 1;41(5):376-381
pubmed: 28334805
Psychopharmacology (Berl). 2016 May;233(10):1981-90
pubmed: 26319160
Psychopharmacology (Berl). 2006 Aug;187(2):154-69
pubmed: 16761129
Basic Clin Pharmacol Toxicol. 2022 Nov;131(5):420-434
pubmed: 36028947
J Psychopharmacol. 2017 May;31(5):589-598
pubmed: 28372480
Neuropsychopharmacology. 2016 Oct;41(11):2704-13
pubmed: 27206266
J Anal Toxicol. 2012 Jul;36(6):444-51
pubmed: 22589523
Neuropsychopharmacology. 2020 Feb;45(3):462-471
pubmed: 31733631
J Psychopharmacol. 2016 Dec;30(12):1305-1312
pubmed: 27562197
Psychopharmacology (Berl). 2004 May;173(3-4):364-75
pubmed: 15071716
J Forensic Sci. 2017 May;62(3):695-699
pubmed: 27921290
Br J Pharmacol. 2013 Jan;168(2):458-70
pubmed: 22897747
Neuropharmacology. 2015 Dec;99:538-45
pubmed: 26302654
Emergencias. 2022 Jun;34(3):174-180
pubmed: 35736521
Addict Biol. 2017 Sep;22(5):1160-1168
pubmed: 27046454
Int J Legal Med. 2016 Mar;130(2):381-5
pubmed: 26071183
Br J Clin Pharmacol. 1990 Dec;30(6):825-8
pubmed: 2288828
Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497
pubmed: 32500209
J Anal Toxicol. 2016 Sep;40(7):543-5
pubmed: 27405363
J Neurosci Methods. 2018 Jul 1;304:39-45
pubmed: 29679703
J Clin Endocrinol Metab. 2011 Sep;96(9):2844-50
pubmed: 21715530
J Med Toxicol. 2012 Mar;8(1):65-8
pubmed: 22160789
Clin Pharmacol Ther. 1994 May;55(5):556-62
pubmed: 7910126
Brain Res Bull. 2016 Sep;126(Pt 1):61-67
pubmed: 26995278
Drug Alcohol Depend. 1994 Jun;35(3):203-9
pubmed: 7956749
J Pharmacol Exp Ther. 2021 Jun;377(3):398-406
pubmed: 33785525
Int J Neuropsychopharmacol. 2014 Mar;17(3):371-81
pubmed: 24103254
J Clin Med. 2022 Feb 15;11(4):
pubmed: 35207278
J Psychopharmacol. 2019 Jul;33(7):831-841
pubmed: 31038382
Sci Rep. 2020 Nov 24;10(1):20442
pubmed: 33235285
Psychopharmacology (Berl). 2014 Oct;231(19):3899-905
pubmed: 24633447
J Anal Toxicol. 2012 Jul;36(6):434-9
pubmed: 22582221
Neuropharmacology. 2018 May 15;134(Pt A):57-64
pubmed: 28882561
Neuropsychopharmacology. 2017 Feb;42(3):649-660
pubmed: 27658484
Neuropsychopharmacology. 2006 May;31(5):1048-55
pubmed: 16160704
Am J Addict. 2016 Aug;25(5):400-7
pubmed: 27419383
J Addict Res Ther. 2012 Dec 1;Suppl 9:
pubmed: 24244886
Drug Metab Dispos. 2009 Oct;37(10):2079-86
pubmed: 19628751
Neuropharmacology. 2015 May;92:90-7
pubmed: 25600245
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:64-72
pubmed: 23603357
Biochem Pharmacol. 2013 Jun 15;85(12):1803-15
pubmed: 23583454
Psychopharmacology (Berl). 2018 Aug;235(8):2349-2356
pubmed: 29855660
J Psychopharmacol. 2021 May;35(5):556-565
pubmed: 33781103
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Forensic Sci Int. 2013 Sep 10;231(1-3):e1-3
pubmed: 23827713
Psychopharmacology (Berl). 2007 May;192(1):111-9
pubmed: 17219216
J Clin Psychopharmacol. 2000 Aug;20(4):455-66
pubmed: 10917407